PDF(Pubmed)
Abstract：
BACKGROUND: Primary hepatocellular carcinoma (HCC) is one of the most prevalent world-wide malignancies. Half of the newly developed HCC occurs in China. Optimizing the strategies for high-risk surveillance and early diagnosis are pivotal for improving 5-year survival. Constructing the scientific non-invasive detection technologies feasible for medical and healthcare institutions is among the key routes for elevating the efficacies of HCC identification and follow-up.
RESULTS: Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence-based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple-biomarker (AFP, AFP-L3%, DCP) based GALAD, GALAD like models for liver cancer.
CONCLUSIONS: The compile of this consensus statement aims to address and push the reasonable application of the triple-biomarker (AFP, AFP-L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.
RESULTS: Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence-based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple-biomarker (AFP, AFP-L3%, DCP) based GALAD, GALAD like models for liver cancer.
CONCLUSIONS: The compile of this consensus statement aims to address and push the reasonable application of the triple-biomarker (AFP, AFP-L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.
摘要：
背景：原发性肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一。新发展的肝癌有一半发生在中国。优化高风险监测和早期诊断策略对于提高5年生存率至关重要。构建适用于医疗保健机构的科学非侵入性检测技术是提高HCC识别和随访有效性的关键途径之一。
结果：根据中国和国际准则，专家共识声明，文献和循证临床实践经验，这一共识声明提出了临床意义，申请科目,三重生物标志物的检测技术和结果解释(AFP，AFP-L3%,DCP)基于GALAD，GALAD像肝癌模型。
结论：本共识声明的汇编旨在解决和推动三重生物标志物（AFP，AFP-L3%,DCP)检测，从而最大限度地提高临床效益，并帮助改善高风险监测，肝癌的早期诊断和预后。
结果：根据中国和国际准则，专家共识声明，文献和循证临床实践经验，这一共识声明提出了临床意义，申请科目,三重生物标志物的检测技术和结果解释(AFP，AFP-L3%,DCP)基于GALAD，GALAD像肝癌模型。
结论：本共识声明的汇编旨在解决和推动三重生物标志物（AFP，AFP-L3%,DCP)检测，从而最大限度地提高临床效益，并帮助改善高风险监测，肝癌的早期诊断和预后。
